Equity Overview
Price & Market Data
Price: $2.15
Daily Change: $0.00 / 0.00%
Daily Range: $2.05 - $2.26
Market Cap: $173,229,040
Daily Volume: 1,100,329
Performance Metrics
1 Week: 1.90%
1 Month: -24.03%
3 Months: 19.44%
6 Months: -8.90%
1 Year: -16.99%
YTD: 19.44%
Company Details
Employees: 226
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.